Affymetrix Microarray Platform Receives FDA Clearance
3,188 Views
Santa Clara CA (OBBeC) - Affymetrix has announced that the U.S. Food and Drug Administration (FDA) has granted regulatory clearance to its GCS3000Dx (GCSDx) platform for in vitro gene expression diagnostic testing. The microarray system was granted clearance along with the Pathwork Tissue of Origin (TOO) Test from Pathwork Diagnostics. This test analyzes a tumour's gene expression profile to aid in diagnosing the source of hard-to-identify tumours and, according to the company, is the first of its kind to receive FDA clearance.
Pathwork is a member of the Powered by Affymetrix (PbA) program, which includes 11 diagnostic companies. There are currently more than 20 different molecular assay tests based on the Affymetrix platform under development by Affymetrix and its PbA Partners.
"Together Affymetrix and Pathwork have developed and now bring to market a very powerful tool to potentially improve cancer diagnostics and subsequent treatment planning and outcome," said Kevin King, president of Affymetrix. "The Pathwork Tissue of Origin Test is supported by extensive analytical and clinical validation data. This not only expands the menu on our diagnostic platform, but opens the door for other gene expression-based diagnostic tests that are currently being developed by Affymetrix and our PbA partners on the GCSDx platform."
Comments